Changes in cytokine profile during local IL-2 therapy in cancer patients

被引:0
|
作者
Tomova, R
Pomakov, J
Jacobs, JJL
Adjarov, D
Popova, S
Altankova, I
Den Otter, W
Krastev, Z
机构
[1] Univ Hosp St Ivan Rilski, Gastrointestinal Clin, Sofia 1431, Bulgaria
[2] Univ Hosp St Ivan Rilski, Dept Clin Immunol, Sofia 1431, Bulgaria
[3] Univ Hosp St Ivan Rilski, Dept Clin Lab, Sofia 1431, Bulgaria
[4] Univ Utrecht, Fac Vet Med, Dept Pathobiol, NL-3508 TD Utrecht, Netherlands
关键词
IL-2; therapy; cytokines; IL-5; IL-10;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Exogenous interleukin 2 (IL-2) can influence the complex cytokine network in vivo. This study investigated the cytokine profile of patients with different malignancies before and after local IL-2 administration. Patients and Methods: The human TH1 / TH2 cytometric bead array (CBA) kit was used to investigate IL-2, IFN gamma, TNF alpha. IL-4, IL-5 and IL- 10 in a control group and in 13 patients. Results: The baseline serum IL-4 levels in patients were lower than in healthy controls, while the baseline ascitic IL-10 levels in patients was higher than in serum. The IL-2 applications induced a strong serum increase in IL-2 and IL-5 and even more in ascites, while IL-10 increased weakly and mainly locally. One month after the start of therapy, the serum IFN gamma had increased in patients, reaching the level of the control group. Conclusion: After local injection, IL-2 probably leaks into the blood circulation. The higher increases of IL-2, IL-5 and IL-10 in ascites compared to the serum suggests that the injected cytokines and their effects are mainly local. The minor increase of the immunosuppressive IL-10 could explain the therapeutic difference between local and systemic IL-2 therapy since IL-10 levels markedly increase after systemic IL-2 therapy. IL-5 was always increased after IL-2 therapy and, consequently, may be a downstream mediator of antitumour responses.
引用
收藏
页码:2037 / 2047
页数:11
相关论文
共 50 条
  • [41] IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside
    Wigginton, JM
    Wiltrout, RH
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (05) : 513 - 524
  • [42] IL-1β, IL-2, IL-4 AND IL-10 PROFILE DURING PORCINE GESTATION
    Velez, C.
    Williamson, D.
    Koncurat, M.
    PLACENTA, 2017, 51 : 116 - 116
  • [43] GENE-THERAPY OF CANCER - USE OF INTERLEUKIN-2 (IL-2) GENE-TRANSFER IN LOCAL IMMUNOTHERAPY
    BUBENIK, J
    LOTZOVA, E
    ZEUTHEN, J
    BUBENIKOVA, D
    SIMOVA, J
    INDROVA, M
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1991, 10 (04) : 213 - 220
  • [44] Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer
    Lissoni, P
    Rovelli, F
    Vellani, D
    Malugani, F
    Bucovec, R
    Chapovalenko, L
    Fumagalli, E
    Gardani, G
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (02): : 146 - 147
  • [45] LOBULAR PANNICULITIS AFTER SUBCUTANEOUS ADMINISTRATION OF INTERLEUKIN-2 (IL-2), AND ITS EXACERBATION DURING INTRAVENOUS THERAPY WITH IL-2
    BAARS, JW
    COENEN, JLLM
    WAGSTAFF, J
    VANDERVALK, P
    PINEDO, HM
    BRITISH JOURNAL OF CANCER, 1992, 66 (04) : 698 - 699
  • [46] IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
    Tomala, Jakub
    Kovar, Marek
    ONCOIMMUNOLOGY, 2016, 5 (03):
  • [47] IMMUNOLOGICAL CHANGES IN PATIENTS WITH CANCER GIVEN INTERLEUKIN-2 (IL-2) IN A PHASE-I TRIAL
    LOTZE, MT
    FRANA, LW
    SEIPP, CA
    SHARROW, SO
    ROSENBERG, SA
    SURGICAL FORUM, 1984, 35 : 407 - 408
  • [48] IMMUNOTHERAPY OF CANCER USING LOCAL-ADMINISTRATION OF LYMPHOID-CELLS TRANSFORMED BY IL-2 CDNA AND CONSTITUTIVELY PRODUCING IL-2
    BUBENIK, J
    SIMOVA, J
    JANDLOVA, T
    IMMUNOLOGY LETTERS, 1990, 23 (04) : 287 - 292
  • [49] IL-2/ IL-2 mAb treatment generates prolonged expansion and increased cytokine production by NKT cells
    Webster, Kylie
    Kyparissoudis, Konstantinos
    Godfrey, Dale
    Sprent, Jonathan
    JOURNAL OF IMMUNOLOGY, 2010, 184
  • [50] Intratumoral injection of IL-2 plasmid followed by electroporation for cancer therapy
    Horton, H
    Planchon, R
    Sawdey, N
    Smith, L
    Rolland, A
    Kaslow, D
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 621 - 621